Bezlotoxumab associated with lower recurrence of C. difficile infection: The MODIFY I and II trials

1. Bezlotoxumab therapy associated with significantly lower rate of recurrent C. difficile infection compared to placebo. 2. Actoxumab not efficacious when administered aloine or in combination with bezlotoxumab in reducing rates of recurrent C. difficile infection. Evidence Rating Level: 1 (excellent) Study Rundown: In hospitalized patients, C. difficile is a widespread cause of infectious diarrhea. An